Detalhe da pesquisa
1.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature
; 603(7903): 942-948, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35322232
2.
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma.
Br J Cancer
; 128(10): 1916-1921, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36927977
3.
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.
Future Oncol
; 19(11): 739-752, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36919706
4.
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy.
Int J Mol Sci
; 25(1)2023 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38203214
5.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet
; 398(10294): 27-40, 2021 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34102137
6.
A Canadian single-centre experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for abdominal malignancies.
Can J Surg
; 65(3): E342-E351, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35580884
7.
Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
Oncologist
; 26(4): e597-e602, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33274825
8.
Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
Oncologist
; 25(11): 916-920, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32716573
9.
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
BMC Cancer
; 19(1): 68, 2019 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30642290
10.
Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
Future Oncol
; 14(3): 223-228, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29318901
11.
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(11): 1467-1482, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28958504
12.
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
Br J Cancer
; 115(8): 974-982, 2016 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27623234
13.
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Cancer
; 121(6): 883-92, 2015 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25377507
14.
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet
; 383(9911): 31-39, 2014 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-24094768
15.
Best Practices for Managing Patients with Unresectable Metastatic Gastric and Gastroesophageal Junction Cancer in Canada.
Curr Oncol
; 31(5): 2552-2565, 2024 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38785472
16.
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D.
Clin Colorectal Cancer
; 23(2): 118-127.e6, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38762348
17.
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E.
Clin Colorectal Cancer
; 23(2): 183-193, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653648
18.
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
J Clin Oncol
; 42(17): 2012-2020, 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38382001
19.
Current and Emerging Role of Monoclonal Antibody-Based First-Line Treatment in Advanced Gastro-Esophageal and Gastric Cancer.
Curr Oncol
; 30(10): 9304-9316, 2023 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37887572
20.
Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases.
Neurooncol Adv
; 5(1): vdad018, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37025758